ClinicalTrials.gg
CompletedNCT05579249Updated Jan 14, 2026Results posted

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

A Phase 4 interventional study of Semaglutide and Orlistat in Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
15th of 143
500 · median 100
Started
2023
with 14 others
Phase 4
40 of 143
20 open now
Registered
54th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 15th largest by enrollment, is one of 15 that started in 2023, is one of 40 in phase 4, and was the 54th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) greater than equal to 30.0 kilogram per meter square (kg/m\^2).
  • Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected or to Wegovy or related products according to the label.
  • Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective method.
  • History of type 1 or type 2 diabetes mellitus.
  • Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.

    Drug: Semaglutide

  • Active comparator
    Other anti-obesity medication

    Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

    Drug: Orlistat · Drug: Phentermine/Topiramate · Drug: Naltrexone/Bupropion · Drug: Liraglutide

Interventions

  • Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.

    Also known as: Wegovy

  • Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

    Also known as: Xenical

  • DrugPhentermine/Topiramate

    Drug pages: Phentermine · Topiramate

    Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

    Also known as: Qsymia

  • DrugNaltrexone/Bupropion

    Drug pages: Naltrexone · Bupropion

    Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

    Also known as: Contrave

  • Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

    Also known as: Saxenda

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

    Number of participants who achieved greater than or equal to 10.0% body weight reduction (yes/no) at week 52 is presented.

    Time frame: At end of treatment (week 52)

Secondary outcomes

  1. Percentage Change in Body Weight

    Percentage change in body weight from week 0 to week 52 is presented.

    Time frame: Baseline (week 0), end of treatment (week 52)

  2. Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain

    The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain.

    Time frame: Baseline (week 0), end of treatment (week 52)

  3. Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)

    Number of participants who achieved more than or equal to 15.0% body weight reduction (yes/no) at week 52 is presented.

    Time frame: At end of treatment (week 52)

  4. Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)

    Number of participants who achieved more than or equal to 20.0% body weight reduction (yes/no) at week 52 is presented.

    Time frame: At end of treatment (week 52)

  5. Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no)

    The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain score ≥ 14.6.

    Time frame: At end of treatment (week 52)

  6. Percentage of Days Covered (PDC) by Study Product

    Percentage of days covered by study product from week 0 to week 52 is presented. The percentage of days covered by the study product is determined by the duration on the study product divided by the planned study duration, multiplied by 100.

    Time frame: From week 0 to week 52

  7. Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)

    Number of participants covered by study product ≥80% of days (yes/no) from week 0 to week 52 is presented.

    Time frame: At end of treatment (week 52)

  8. Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)

    Work Limitations Questionnaire (WLQ-25) is a 25-item questionnaire that measures how health problems affect job performance and productivity over the past two weeks, using a 5-point Likert scale. It covers four domains: Time Management (5 items), Physical Demands (6), Mental/Interpersonal (9), and Output Demands (5). Each item is scored from 1 to 5, with subscale scores calculated as the average item score, then converted to a 0-100 scale using the formula: WLQ Scale Score= 25 × (average item score - 1). Thus, each subscale ranges from 0 (no limitation) to 100 (maximum limitation). The WLQ total score is computed by applying specific weights to each subscale and summing them: 0.00048 × Time scale + 0.00036 × Physical scale + 0.00096 × Mental/Interpersonal scale + 0.00106 × Output scale. This total is then transformed into the proportion of productivity loss using the formula: (1 - exp(-total score)).

    Time frame: Baseline (week 0), end of treatment (week 52)

07

Results

Posted Jan 14, 2026

Participant flow

The study was conducted at one site in United States.

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Started250250
Full analysis set250250
Safety analysis set242242
Completed214191
Not completed3659
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up3352
Withdrew: Physician decision22
Withdrew: Death02

Outcome measures

PrimaryNumber of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

Number of participants who achieved greater than or equal to 10.0% body weight reduction (yes/no) at week 52 is presented.

Time frame:
At end of treatment (week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)
ParticipantsSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Yes13261
No75116
Statistical analysis
  • Semaglutide 2.4 mg vs Other Anti-obesity Medications (AOMs) · Regression, Linear · p = <0.0001 · Odds ratio (or): 3.18 · 95% CI 2.12 to 4.78
SecondaryPercentage Change in Body Weight

Percentage change in body weight from week 0 to week 52 is presented.

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Percentange change in body weight
Percentage Change in Body Weight
Percentange change in body weightSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Percentage Change in Body Weight-13.6 ± 8.7-7.4 ± 7.3
SecondaryChange in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain

The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain.

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain
Score on a scaleSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain25.6 ± 21.222.6 ± 24.4
SecondaryNumber of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)

Number of participants who achieved more than or equal to 15.0% body weight reduction (yes/no) at week 52 is presented.

Time frame:
At end of treatment (week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)
ParticipantsSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Yes9325
No114152
SecondaryNumber of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)

Number of participants who achieved more than or equal to 20.0% body weight reduction (yes/no) at week 52 is presented.

Time frame:
At end of treatment (week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)
ParticipantsSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Yes498
No158169
SecondaryNumber of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no)

The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain score ≥ 14.6.

Time frame:
At end of treatment (week 52)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no)
ParticipantsSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Yes138108
No5155
SecondaryPercentage of Days Covered (PDC) by Study Product

Percentage of days covered by study product from week 0 to week 52 is presented. The percentage of days covered by the study product is determined by the duration on the study product divided by the planned study duration, multiplied by 100.

Time frame:
From week 0 to week 52
Reported as:
Mean · Percentage of days covered
Percentage of Days Covered (PDC) by Study Product
Percentage of days coveredSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Percentage of Days Covered (PDC) by Study Product83.7 ± 24.670.8 ± 28.6
SecondaryNumber of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)

Number of participants covered by study product ≥80% of days (yes/no) from week 0 to week 52 is presented.

Time frame:
At end of treatment (week 52)
Reported as:
Count of participants · Participants
Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)
ParticipantsSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Yes168113
No82137
SecondaryChange in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)

Work Limitations Questionnaire (WLQ-25) is a 25-item questionnaire that measures how health problems affect job performance and productivity over the past two weeks, using a 5-point Likert scale. It covers four domains: Time Management (5 items), Physical Demands (6), Mental/Interpersonal (9), and Output Demands (5). Each item is scored from 1 to 5, with subscale scores calculated as the average item score, then converted to a 0-100 scale using the formula: WLQ Scale Score= 25 × (average item score - 1). Thus, each subscale ranges from 0 (no limitation) to 100 (maximum limitation). The WLQ total score is computed by applying specific weights to each subscale and summing them: 0.00048 × Time scale + 0.00036 × Physical scale + 0.00096 × Mental/Interpersonal scale + 0.00106 × Output scale. This total is then transformed into the proportion of productivity loss using the formula: (1 - exp(-total score)).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)
Score on a scaleSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)-0.034 ± 0.070-0.016 ± 0.048

Adverse events

Collected over From week 0 to week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 2.4 mg0/250 (0%)3/242 (1.2%)0/242 (0%)
Other Anti-obesity Medications (AOMs)2/250 (0.8%)8/242 (3.3%)0/242 (0%)
Most frequent serious events
Most frequent serious events
EventSemaglutide 2.4 mgOther Anti-obesity Medications (AOMs)
CholecystitisHepatobiliary disorders0/2422/242
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2422/242
Amyotrophic lateral sclerosisNervous system disorders1/2420/242
Atrioventricular block completeCardiac disorders1/2420/242
Drug hypersensitivityImmune system disorders0/2421/242
Cardiac arrestCardiac disorders0/2421/242
DiverticulitisInfections and infestations0/2421/242
Road traffic accidentInjury, poisoning and procedural complications0/2421/242
Suicide attemptPsychiatric disorders0/2421/242

Baseline characteristics

Full analysis set included all randomized participants.

Age, Continuous
Age, Continuous(Years)Semaglutide 2.4 mgOther Anti-obesity Medications (AOMs)Total
Mean40.6 ± 9.342.0 ± 10.341.3 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgOther Anti-obesity Medications (AOMs)Total
Female225223448
Male252752
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgOther Anti-obesity Medications (AOMs)Total
Hispanic or Latino159150309
Not Hispanic or Latino91100191
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 2.4 mgOther Anti-obesity Medications (AOMs)Total
American Indian or Alaska Native10818
Asian17724
Native Hawaiian or Other Pacific Islander516
Black or African American232750
White193202395
More than one race257
Unknown or Not Reported000
08

Study locations

1 site
  • Nutrition Research Centre
    Loma Linda, California 92354, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Nov 2024, 22 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 13, 2022
StartActual
Jan 19, 2023
Primary completionActual
Nov 27, 2024
CompletionActual
Nov 27, 2024
Results first posted
Jan 14, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05579249
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Jan 19, 2023
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024
Results posted
Jan 14, 2026
Last update
Jan 14, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion